References: What makes a compliant Phase III and pre-launch patient advocacy strategy?

711

Views

CrossRef citations to date

Altmetric

References

Francer J, Izquierdo JZ, Music T, Narsai K, Nikidis C, Simmonds H, etal. Ethical pharmaceutical promotion and communications worldwide: Codes and regulations. Philos Ethics Humanit Med. 2014; 9: 7.
PubMed Web of Science ®Google Scholar
Association of the British Pharmaceutical Industry. ABPI code of practice 2016. Available from: http://www.pmcpa.org.uk/thecode/Documents/Code of Practice 2016.pdf.
Google Scholar
International Federation of Pharmaceutical Manufacturers and Associations. IFPMA code of practice. Available from: http://www.ifpma.org.
Google Scholar
EFPIA code on the relationship between the pharmaceutical industry and patient organisations. 2011. Available from: http://transparency.efpia.eu/uploads/Modules/Documents/code_po2011.pdf.
Google Scholar
Transparency International. Corruption in the pharmaceutical industry. 2016. Available from: http://www.transparency.org.uk/publications/corruption-in-the-pharmaceutical-sector/.
Google Scholar
Messina J, Grainger D. A pilot study to identify areas for further improvements in patient and public involvement in health technology assessments for medicines. Patient. 2012; 5(3): 199–211.
Google Scholar
Facey K, Boivin A, Gracia J, Hansen HP, Scalzo A, Mossman J, etal. Patients perspectives in health technology assessment: A route to robust evidence and far deliberation. Int J Technol Assess Health Care. 2010; 26(3): 334–40.
PubMed Web of Science ®Google Scholar